These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Is ganglioside GM1 effective in the treatment of stroke? Braune S Drugs Aging; 1991 Jan; 1(1):57-66. PubMed ID: 1794005 [TBL] [Abstract][Full Text] [Related]
23. Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study. Schneider JS; Roeltgen DP; Mancall EL; Chapas-Crilly J; Rothblat DS; Tatarian GT Neurology; 1998 Jun; 50(6):1630-6. PubMed ID: 9633704 [TBL] [Abstract][Full Text] [Related]
24. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Heiss WD; Brainin M; Bornstein NM; Tuomilehto J; Hong Z; Stroke; 2012 Mar; 43(3):630-6. PubMed ID: 22282884 [TBL] [Abstract][Full Text] [Related]
25. Hypoxic-ischemic damage and the neuroprotective effects of GM1 ganglioside. Leon A; Lipartiti M; Seren MS; Lazzaro A; Mazzari S; Koga T; Toffano G; Skaper SD Stroke; 1990 Nov; 21(11 Suppl):III95-7. PubMed ID: 2237992 [TBL] [Abstract][Full Text] [Related]
26. Monosialoganglioside effects following cerebral ischemia: relationship with anti-neuronotoxic and pro-neuronotrophic effects. Lipartiti M; Seren MS; Lazzaro A; Koga T; Mazzari S; Facci L; Fusco M; Toffano G; Leon A Acta Neurobiol Exp (Wars); 1990; 50(4-5):489-94. PubMed ID: 2130663 [TBL] [Abstract][Full Text] [Related]
27. The effect of Ginkgo biloba on functional outcome of patients with acute ischemic stroke: a double-blind, placebo-controlled, randomized clinical trial. Oskouei DS; Rikhtegar R; Hashemilar M; Sadeghi-Bazargani H; Sharifi-Bonab M; Sadeghi-Hokmabadi E; Zarrintan S; Sharifipour E J Stroke Cerebrovasc Dis; 2013 Nov; 22(8):e557-63. PubMed ID: 23871729 [TBL] [Abstract][Full Text] [Related]
29. Trafermin for stroke recovery: is it time for another randomized clinical trial? Paciaroni M; Bogousslavsky J Expert Opin Biol Ther; 2011 Nov; 11(11):1533-41. PubMed ID: 21883031 [TBL] [Abstract][Full Text] [Related]
30. Gangliosides (GM1 and AGF2) reduce mortality due to ischemia: protection of membrane function. Karpiak SE; Li YS; Mahadik SP Stroke; 1987; 18(1):184-7. PubMed ID: 3027926 [TBL] [Abstract][Full Text] [Related]
31. [Past, present and future of neuroprotection]. Mracek J Cas Lek Cesk; 2010; 149(12):586-90. PubMed ID: 21387585 [TBL] [Abstract][Full Text] [Related]
32. [Ganglioside GM1 in early strokes]. Kuczyńska-Zardzewiały A; Kruszewska J; Lechowicz W; Członkowska A Neurol Neurochir Pol; 1994; 28(5):643-9. PubMed ID: 7862232 [TBL] [Abstract][Full Text] [Related]
33. Effect of the ganglioside GM1 on neurologic function, electroencephalogram amplitude, and histology in chronic middle cerebral artery occlusion in cats. Komatsumoto S; Greenberg JH; Hickey WF; Reivich M Stroke; 1988 Aug; 19(8):1027-35. PubMed ID: 3400101 [TBL] [Abstract][Full Text] [Related]
34. GM1 ganglioside treatment after global ischemia protects changes in membrane fatty acids and properties of Na+, K+-ATPase and Mg2+-ATPase. Mahadik SP; Hawver DB; Hungund BL; Li YS; Karpiak SE J Neurosci Res; 1989 Nov; 24(3):402-12. PubMed ID: 2531806 [TBL] [Abstract][Full Text] [Related]